Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) Director Kush Parmar sold 10,494 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $7.00, for a total value of $73,458.00. Following the completion of the transaction, the director directly owned 2,836,098 shares in the company, valued at approximately $19,852,686. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kush Parmar also recently made the following trade(s):
- On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total value of $647,108.00.
- On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $358,371.45.
- On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $11,768.30.
- On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.
Entrada Therapeutics Stock Up 1.3%
Shares of NASDAQ:TRDA opened at $7.04 on Wednesday. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The stock has a market cap of $274.14 million, a price-to-earnings ratio of -1.78 and a beta of -0.26. The business has a 50-day moving average price of $6.87 and a 200-day moving average price of $9.65.
Analyst Ratings Changes
Several analysts have recently commented on TRDA shares. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Roth Capital set a $10.00 target price on shares of Entrada Therapeutics in a report on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Guggenheim lowered their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.50.
Get Our Latest Analysis on Entrada Therapeutics
More Entrada Therapeutics News
Here are the key news stories impacting Entrada Therapeutics this week:
- Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
- Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
- Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
- Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
- Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
- Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of TRDA. BlackRock Inc. acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $19,013,000. Millennium Management LLC lifted its stake in shares of Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the period. Citadel Advisors LLC boosted its holdings in Entrada Therapeutics by 234.5% during the third quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after buying an additional 235,384 shares in the last quarter. Baker BROS. Advisors LP boosted its holdings in Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after buying an additional 206,911 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in Entrada Therapeutics by 115.3% during the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after buying an additional 154,143 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.
About Entrada Therapeutics
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Stories
- Five stocks we like better than Entrada Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
